AR117694A1 - COMPUESTO AGONISTA DEL RECEPTOR THRb Y PREPARACIÓN Y USO DEL MISMO - Google Patents

COMPUESTO AGONISTA DEL RECEPTOR THRb Y PREPARACIÓN Y USO DEL MISMO

Info

Publication number
AR117694A1
AR117694A1 ARP190103650A ARP190103650A AR117694A1 AR 117694 A1 AR117694 A1 AR 117694A1 AR P190103650 A ARP190103650 A AR P190103650A AR P190103650 A ARP190103650 A AR P190103650A AR 117694 A1 AR117694 A1 AR 117694A1
Authority
AR
Argentina
Prior art keywords
thrb
receptor
preparation
same
agonist compound
Prior art date
Application number
ARP190103650A
Other languages
English (en)
Inventor
Ben Li
Shanghai Yu
Original Assignee
Terns Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Terns Inc filed Critical Terns Inc
Publication of AR117694A1 publication Critical patent/AR117694A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Un compuesto representado por la fórmula (1) y una sal farmacéuticamente aceptable del mismo. El compuesto mejora la selectividad por THRa mientras que mantiene una buena actividad agonista de THRb, lo que mejora las propiedades del fármaco terminado.
ARP190103650A 2018-12-13 2019-12-12 COMPUESTO AGONISTA DEL RECEPTOR THRb Y PREPARACIÓN Y USO DEL MISMO AR117694A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201811527414.4A CN111320609A (zh) 2018-12-13 2018-12-13 一种THRβ受体激动剂化合物及其制备方法和用途

Publications (1)

Publication Number Publication Date
AR117694A1 true AR117694A1 (es) 2021-08-25

Family

ID=71071432

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190103650A AR117694A1 (es) 2018-12-13 2019-12-12 COMPUESTO AGONISTA DEL RECEPTOR THRb Y PREPARACIÓN Y USO DEL MISMO

Country Status (17)

Country Link
US (3) US11084802B2 (es)
EP (1) EP3893889A4 (es)
JP (1) JP2022512482A (es)
KR (1) KR20210102328A (es)
CN (3) CN111320609A (es)
AR (1) AR117694A1 (es)
AU (1) AU2019398339A1 (es)
BR (1) BR112021010871A2 (es)
CA (1) CA3120880A1 (es)
CL (1) CL2021001521A1 (es)
CO (1) CO2021008817A2 (es)
IL (2) IL310699A (es)
MA (1) MA54471A (es)
MX (1) MX2021006908A (es)
PE (1) PE20211788A1 (es)
SG (1) SG11202106194TA (es)
WO (1) WO2020123827A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI804870B (zh) 2012-09-17 2023-06-11 美商瑪德瑞高製藥公司 用以合成甲狀腺激素類似物及其多形體之方法
AU2019287679B2 (en) 2018-06-12 2022-04-21 Xizang Haisco Pharmaceutical Co., Ltd. Thyroid hormone receptor agonists and uses thereof
CA3114015A1 (en) 2018-10-12 2020-04-16 Terns, Inc. Thyroid hormone receptor beta agonist compounds
CN111320609A (zh) 2018-12-13 2020-06-23 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
MA55890A (fr) 2019-05-08 2022-03-16 Aligos Therapeutics Inc Modulateurs de thr-beta et leurs procédés d'utilisation
TW202108556A (zh) * 2019-05-10 2021-03-01 大陸商深圳微芯生物科技股份有限公司 一種噠嗪酮衍生物及其應用
WO2020239076A1 (zh) * 2019-05-29 2020-12-03 南京明德新药研发有限公司 作为甲状腺素受体-β激动剂的哒嗪酮类衍生物及其应用
TW202128668A (zh) * 2019-12-16 2021-08-01 大陸商江蘇恆瑞醫藥股份有限公司 并環類衍生物、其製備方法及其在醫藥上的應用
CN115811972A (zh) * 2020-05-13 2023-03-17 拓臻制药公司 肝脏病症的组合治疗
MX2023002308A (es) 2020-08-25 2023-07-11 Lilly Co Eli Polimorfos de un inhibidor de ssao.
WO2022053028A1 (zh) * 2020-09-10 2022-03-17 南京明德新药研发有限公司 1,2,4-三嗪-3,5(2h,4h)-二酮类化合物及其应用
CA3192169A1 (en) * 2020-09-17 2022-03-24 Sunshine Lake Pharma Co., Ltd. A compound as a thyroid hormone beta receptor agonist and use thereof
KR20230117564A (ko) * 2020-10-23 2023-08-08 마드리갈 파마슈티칼스, 인크. 갑상선 호르몬 유사체의 중간체로서 6-(4-니트로-페녹시)-2h-피리다진-3-온 및 6-(4-아미노-페녹시)-2h-피리다진-3-온 유도체의 제조 공정
US11858913B2 (en) 2020-11-06 2024-01-02 Aligos Therapeutics, Inc. Bicyclic pyridazinones and methods of use thereof
CN116925045A (zh) * 2020-12-15 2023-10-24 中国科学院上海药物研究所 甲状腺素受体β选择性激动剂化合物、其药物组合物和用途
CN114685450A (zh) 2020-12-30 2022-07-01 昆药集团股份有限公司 2-吡啶酮类衍生物及其制备方法和在医药上的应用
IL305495A (en) * 2021-03-03 2023-10-01 Terns Pharmaceuticals Inc Thyroid hormone receptor beta agonist compounds
CA3238082A1 (en) * 2021-11-11 2023-05-19 Terns Pharmaceuticals, Inc. Combination of a ssao inhibitor and thr-beta agonist for use in the treatment of liver disorders
WO2023083288A1 (en) * 2021-11-11 2023-05-19 Terns Pharmaceuticals, Inc. TREATMENT OF LIVER DISORDERS WITH A THR-β AGONIST
WO2023154842A1 (en) * 2022-02-10 2023-08-17 Madrigal Pharmaceuticals, Inc. Thr beta analogs and uses thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0377903A3 (de) * 1989-01-09 1991-07-17 Bayer Ag Substituierte Hexahydro-1,2,4-triazindione, Verfahren zu ihrer Herstellung, Zwischenprodukte dafür und ihre Verwendung
US6787652B1 (en) 1999-09-30 2004-09-07 Pfizer, Inc. 6-Azauracil derivatives as thyroid receptor ligands
EP1347959A1 (de) * 2000-12-27 2003-10-01 Bayer Aktiengesellschaft Indol-derivate
EP1471049A4 (en) 2002-01-30 2006-08-16 Kissei Pharmaceutical NEW THYROIDIAN HORMONE RECEPTOR LIGAND, MEDICINAL PREPARATIONS CONTAINING THE SAME AND USE THEREOF
AU2003225305A1 (en) 2002-05-08 2003-11-11 Bristol-Myers Squibb Company Pyridine-based thyroid receptor ligands
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
FR2882750B1 (fr) 2005-03-03 2007-05-11 Pierre Fabre Medicament Sa Derives de 1,2,4-triazines, leur preparation et leur application en therapeutique humaine
GB0513692D0 (en) 2005-07-04 2005-08-10 Karobio Ab Novel pharmaceutical compositions
MX2008000818A (es) * 2005-07-21 2008-03-18 Hoffmann La Roche Derivados de piridazinona como agonistas del receptor de la hormona tiroidea.
EP2423194B1 (en) 2009-04-20 2014-04-16 Mitsubishi Tanabe Pharma Corporation Novel thyroid hormone beta receptor agonist
WO2011038207A1 (en) 2009-09-25 2011-03-31 Metabasis Therapeutics, Inc. Phosphorus-containing thyroid hormone receptor agonists and methods of use
KR20140090678A (ko) 2011-11-14 2014-07-17 세파론, 인코포레이티드 AXL 및 c-MET 키나제 억제제로서의 우라실 유도체
CN103130723B (zh) 2011-11-30 2015-01-14 成都地奥制药集团有限公司 一种多聚(adp-核糖)聚合酶抑制剂
CN102898377B (zh) * 2012-02-14 2016-01-20 南京圣和药业股份有限公司 一类酞嗪酮衍生物及其用途
CN107074823B (zh) 2014-09-05 2021-05-04 基因泰克公司 治疗性化合物及其用途
KR20230156159A (ko) * 2016-10-18 2023-11-13 마드리갈 파마슈티칼스, 인크. Thr-베타 아고니스트로 간 질환 또는 지질 질환을 치료하는 방법
CN109574995B (zh) 2018-01-23 2020-07-24 深圳市塔吉瑞生物医药有限公司 取代的哒嗪酮化合物
AU2019287679B2 (en) * 2018-06-12 2022-04-21 Xizang Haisco Pharmaceutical Co., Ltd. Thyroid hormone receptor agonists and uses thereof
CN112601674A (zh) 2018-08-24 2021-04-02 全耐塑料高级创新研究公司 包括挡板和穿过该挡板的流体输送线的流体储箱用组件
EP3840755A4 (en) 2018-08-24 2022-04-20 Terns, Inc. THYROID HORMONE BETA RECEPTOR AGONIST COMPOUNDS
CA3114015A1 (en) 2018-10-12 2020-04-16 Terns, Inc. Thyroid hormone receptor beta agonist compounds
KR20210076932A (ko) 2018-10-12 2021-06-24 인벤티스바이오 컴퍼니 리미티드 갑상선 호르몬 수용체 작용제
CN111320609A (zh) 2018-12-13 2020-06-23 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
CN111484481A (zh) 2019-01-26 2020-08-04 察略盛医药科技(上海)有限公司 哒嗪酮类衍生物、其制备方法及其在医药上的用途
WO2020169069A1 (en) 2019-02-21 2020-08-27 Nanjing Ruijie Pharma Co., Ltd. Novel compounds and their uses as thyroid hormone receptor agonists
WO2020239076A1 (zh) 2019-05-29 2020-12-03 南京明德新药研发有限公司 作为甲状腺素受体-β激动剂的哒嗪酮类衍生物及其应用

Also Published As

Publication number Publication date
JP2022512482A (ja) 2022-02-04
KR20210102328A (ko) 2021-08-19
PE20211788A1 (es) 2021-09-09
SG11202106194TA (en) 2021-07-29
CN116444498A (zh) 2023-07-18
IL283362A (en) 2021-07-29
US11084802B2 (en) 2021-08-10
EP3893889A4 (en) 2022-08-03
CA3120880A1 (en) 2020-06-18
CN113194958A (zh) 2021-07-30
WO2020123827A1 (en) 2020-06-18
CN111320609A (zh) 2020-06-23
MA54471A (fr) 2021-10-20
TW202039470A (zh) 2020-11-01
CO2021008817A2 (es) 2021-07-19
IL310699A (en) 2024-04-01
BR112021010871A2 (pt) 2021-08-31
US11034676B2 (en) 2021-06-15
CL2021001521A1 (es) 2022-01-28
CN113194958B (zh) 2023-05-23
IL283362B1 (en) 2024-03-01
US20200190064A1 (en) 2020-06-18
EP3893889A1 (en) 2021-10-20
US20200399249A1 (en) 2020-12-24
MX2021006908A (es) 2021-07-07
US20230278988A1 (en) 2023-09-07
AU2019398339A1 (en) 2021-06-10

Similar Documents

Publication Publication Date Title
AR117694A1 (es) COMPUESTO AGONISTA DEL RECEPTOR THRb Y PREPARACIÓN Y USO DEL MISMO
DOP2020000037A (es) Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
UY38297A (es) Compuestos derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona, composiciones, métodos y usos de los mismos
BR112022008375A2 (pt) Composto cíclico heterocíclico fundido substituído, método de preparação e uso farmacêutico deste
EA202190802A2 (ru) Производные пиразолопиридина, обладающие эффектом агониста рецептора glp-1
AR111693A1 (es) Compuestos de 5-metil-1,3,4-oxadiazol-2-ilo con actividad inhibitoria de oga
UY36275A (es) Compuestos aminopirimidinilo
CO2017000222A2 (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
MA40059A (fr) Inhibiteurs de la phosphatidylinositol 3-kinase
MA39335B1 (fr) Inhibiteurs mgat2 de dihydropyridinone à substitution tétrazolone
BR112018005589A2 (pt) “composto, composição farmaceuticamente aceitável, e, uso de um composto”
CL2018002583A1 (es) Derivado de morfolina
MX2022006783A (es) Nuevos derivados de metilquinazolinona.
CL2021003455A1 (es) Análogos de 3-(5-meti l-1 ,3-tiazol-2-1 l)-n--{( 1 r)-1-[2-(trifluoro-metil)pirimidin-5-il]etil}benzamida
BR112021026397A2 (pt) Antagonista de ep2
MX2020003732A (es) Derivado de anillo fusionado como inhibidor del receptor a2a.
EA201891682A1 (ru) Производное азациклического амида, способ его получения и фармацевтическое применение
MY197561A (en) Composition for increasing expression of pgc-1?
PH12020551297A1 (en) Compounds having s1p5 receptor agonistic activity
CO2019013254A2 (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
AR053122A1 (es) Monohidrato de di-s-camsilato de 5((2r,5s)-5-metil-4-propilmorfolin-2-il)piridin-2-amina, agonista de dopamina
BR112019006371A2 (pt) compostos, composições farmacêuticas, uso de um composto ou composição e kits
CL2019001617A1 (es) Preparación líquida parenteral que comprende compuesto de carbamato.
CL2019003249A1 (es) Protocolo mejorado para el tratamiento de nefritis lúpica.
BR112018075817A2 (pt) composto de fórmula (i), medicamento e composição farmacêutica